Here we describe the proteomic identification of the novel cell surface antigen SAIL (Surface Antigen In Leukemia) and the preclinical characterization of ADCs with potent in vitro and in vivo activity against SAIL-expressing hematologic tumors. This evidence concerns the gene C16orf54 and hematopoietic and lymphoid system neoplasm.